XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
Aug. 31, 2020
USD ($)
Program
Oct. 31, 2018
Program
Jun. 30, 2023
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
2018 Gilead Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research term     3 years                
Number of licensed product | Program     5                
Non-refundable upfront payment received           $ 50,000,000   $ 50,000,000      
Amended Gilead Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research term   7 years                  
Number of licensed product | Program   15                  
Non-refundable upfront payment received           $ 125,000,000          
Milestone payments receivable   $ 410,000,000                  
Temporary equity, par value   125,000,000                  
Revenue recognized, cumulative catch-up adjustment         $ (11,300,000)            
Research extension fee                   $ 12,000,000 $ 12,000,000
License fee amount $ 5,000,000                    
Contract with customer liability, revenue recognized       $ 5,000,000              
Amended Gilead Agreement [Member] | Minimum [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Ownership percentage in common stock           10.00%          
Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Temporary equity, par value   $ 20,000,000                  
Gilead Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Transaction price allocated to performance obligation           $ 199,000,000          
Cummulative research extension fee           24,000,000          
Short-term deferred revenue           27,100,000     $ 31,800,000    
Long-term deferred revenue           70,700,000     $ 92,100,000    
Collaboration Revenue [Member] | Gilead Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Contract with customer liability, revenue recognized           $ 26,100,000 $ 18,400,000